Transaction Details
Alivira Animal Health Limited, Ireland, a step-down wholly owned subsidiary of Viyash Scientific Limited, has entered into a binding agreement on June 8, 2026 for the acquisition of 100% shareholding of BioForLife Italia s.r.l., Milan, Italy.
Financial Terms
- Total Consideration: EUR 16.975 million
- Upfront Payment: EUR 15.0 million payable at closing
- Deferred Consideration: EUR 1.975 million, payable in accordance with transaction document terms
- Payment Method: Cash consideration
Target Company Information
Name: BioForLife Italia s.r.l., Milan, Italy
Business: Marketing and distribution of animal health/veterinary products for companion animals including medicines, nutraceuticals and testing kits
Date of Incorporation: March 24, 2010
Geographic Presence: Primarily Italy
Financial Performance:
- CY 2023 Sales: EUR 7.1 million
- CY 2024 Sales: EUR 8.3 million
- CY 2025 Sales: EUR 9.0 million
Strategic Rationale
The acquisition is intended to strengthen and scale the Company's presence in Italy in the companion animal segment through an established front-end platform, customer reach and product capabilities.
Regulatory Approvals Required
Notification under Italian Golden Power Laws (Decree-Law No. 21/2012) and other applicable statutory and regulatory approvals.
Transaction Timeline
- Initial closing expected within 3 months from execution of binding agreement (June 8, 2026)
- Deferred consideration expected to be settled within 12 months from closing or earlier upon occurrence of relevant triggers
- Subject to fulfilment of conditions precedent
Related Party Status
The acquisition does not fall within related party transactions. The promoter/promoter group/group companies do not have any interest in the target entity.
Industry Classification
Pharmaceuticals - Animal Health / Veterinary Products - Companion Animal segment